IP Library Granted Patent US 8,802,643
Granted Patent B1
US 8,802,643 · App. 13/216,855 · Granted Aug 12, 2014

Method for the treatment of malignancies

Inventors: Richard Heller (Norfolk, VA); Loree C. Heller (Norfolk, VA)
Assignee: University of South Florida
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,802,643
App. No.
13/216,855
Granted
Aug 12, 2014
Kind
B1
Abstract

A method of treating cancerous tumors is presented herein. The method includes injecting an effective dose of a plasmid encoded for IL-12, B7-1 or IL-15 into a cancerous tumor and subsequently administering at least one high voltage, short duration pulse to the tumor. The electroporation pulses may be administered at least 700V/cm for a duration of less than 1 millisecond. The intratumor treatments with electroporation may be administered in at least a two-treatment protocol with the time between treatments being about 7 days. The intratumor treatments with electroporation may be administered in a three-treatment protocol with a time of four days between the first and second treatments and a time of three days between the second and third treatments. It was found that the intratumor treatments using electroporation not only resulted in tumor regression but also induced an immune memory response which prevented the formation of new tumors.

Claims (14)

1. A method of treating a cancerous tumor, the method comprising:

injecting the cancerous tumor with an effective dose of plasmid coding for B7-1; and

administering electroporation therapy to the tumor wherein the tumor expresses the B7-1 after electroporation, the electroporation therapy comprising the administration of at least one pulse having a field strength of at least 700V/cm and a duration of less than 1 millisecond resulting in the regression of the cancerous tumor and prevention of formation of new tumors.

2. The method of claim 1 , wherein the cancerous tumor is selected from the group comprising, melanoma, Merkel cell carcinoma, T-cell lymphoma, squamous cell carcinoma, pancreatic cancer, and hepatocellular carcinoma.

3. The method of claim 1 , wherein the at least one pulse delivered to the tumor is about 1300V/cm.

4. The method of claim 1 , wherein the duration of the at least one pulse is about 100 microseconds.

5. The method of claim 1 , wherein injecting the cancerous tumor with an effective dose of plasmid coding for B7-1 and administering electroporation therapy to the tumor further comprises:

administering a first treatment at time T1, wherein the first treatment comprises injecting the cancerous tumor with a first effective dose of plasmid coding for B7-1 and administering a first electroporation therapy to the tumor at time T1, the first electroporation therapy comprising the administration of at least one pulse having a field strength of at least 700V/cm and a duration of less than 1 millisecond; and

administering a second treatment at time T2, wherein time T2 is a time later than time T1, wherein the second treatment comprises injecting the cancerous tumor with a second effective dose of plasmid coding for B7-1 and administering a second electroporation therapy to the tumor at time T2, the second electroporation therapy comprising the administration of at least one pulse having a field strength of at least 700V/cm and a duration of less than 1 millisecond.

6. The method of claim 5 , wherein the duration between time T1 and T2 is seven days.

7. The method of claim 5 , further comprising:

administering a third treatment at time T3, wherein time T3 is a time later than time T2, wherein the third treatment comprises injecting the cancerous tumor with a third effective dose of plasmid coding for B7-1 and administering a third electroporation therapy to the tumor, the third electroporation therapy comprising the administration of at least one pulse having a field strength of at least 700V/cm and a duration of less than 1 millisecond.

8. The method of claim 5 , wherein the duration between time T1 and T2 is four days.

9. The method of claim 7 , wherein the duration between time T2 and T3 is three days.

Assignments (2)
CONFIRMATORY LICENSE Recorded Sep 12, 2016
From: UNIVERSITY OF SOUTH FLORIDA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039984/0514 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2011
From: HELLER, RICHARD; LUCAS, MELINDA LEE; UGEN, KENNETH E.; HELLER, LOREE C.
To: UNIVERSITY OF SOUTH FLORIDA
Reel/Frame 027084/0889 →
Continuity (3)
Continuation In Part 11164626 · Nov 30, 2005
Continuation PCTUS2004017153 · Jun 1, 2004
Provisional Application 60320239 · May 30, 2003